Einstein-Montefiore Researcher Will Test Nanoparticles Against Pancreatic Cancer

The research – carried out by a group of five institutions, including Einstein, that comprise the Texas Center for Cancer Nanomedicine – could lead to novel ways to diagnose and treat pancreatic and ovarian cancer using nanoparticles.

Nanoparticles are engineered materials that are 100 nanometers or less in size. (A nanometer is one billionth of a meter.) Nanoparticles impregnated with drugs are called nanomedicines.

“We will be investigating nanomedicines for both imaging and treating pancreatic tumors,” said Einstein-Montefiore principal investigator Steven Libutti, M.D., professor and vice chair of surgery at Einstein and Montefiore, director of the Montefiore-Einstein Center for Cancer Care, and associate director for clinical services of the Albert Einstein Cancer Center. “Our part of the consortium is developing nanoparticles that will specifically target unique aspects of the blood vessels found in pancreatic adenocarcinomas and pancreatic neuroendocrine tumors.”

Pancreatic cancer is the fourth-leading cause of all cancer deaths. Currently, there is no test for early detection of the disease, which killed nearly 37,000 people in 2010. Only 5.6 percent of people diagnosed with pancreatic cancer live for five years or longer, according to the National Cancer Institute.

Dr. Libutti has developed mice that are genetically programmed to form pancreatic tumors that mimic those seen in people. These mice will be used for testing a variety of nanoparticle-based drugs produced by other collaborators. Such studies will reveal whether the particles can home in on disease locations and deliver therapeutic benefits. Dr. Libutti’s clinical practice involves the surgical management of patients with cancer, including those with pancreatic cancer. A main focus of his research is the formation of new blood vessels that nourish tumors.

Identifying the most promising nanoparticle-based drugs for pancreatic as well as ovarian cancer will take several years. Clinical trials are not likely to begin until the end of the five-year project.

In addition to Einstein the other institutions that are members of the Texas Center for Cancer Nanomedicine involved in the nanotech consortium are the University of Texas MD Anderson Cancer Center, the University of Texas Health Science Center at Houston, the Methodist Hospital Research Institute, and Rice University.

About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2010-2011 academic year, Einstein is home to 724 M.D. students, 256 Ph.D. students, 122 students in the combined M.D./Ph.D. program, and 375 postdoctoral research fellows. The College of Medicine has 2,770 fulltime faculty members located on the main campus and at its clinical affiliates. In 2009, Einstein received more than $135 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five medical centers in the Bronx, Manhattan and Long Island – which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein – the College of Medicine runs one of the largest post-graduate medical training programs in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.einstein.yu.edu.

Media Contact

Kim Newman Newswise Science News

More Information:

http://www.einstein.yu.edu

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Distance learning can improve women’s access to vocational training as animal health care practitioners in Nepal. Image Credit: Heifer International

Hybrid Job Training Boosts Women’s Participation in Nepal

Globally, women’s workforce participation is about 25% lower than men’s, often due to barriers such as domestic responsibilities and cultural norms. Vocational training can increase employment opportunities, but women may…

CO2release increase under repeated drying-rewetting cycles (DWCs). Image Credit: Suzuki, Nagano et al., 2025 SOIL

Drying and Rewetting Cycles Boost Soil CO2 Emissions

Niigata, Japan – The amount of carbon dioxide (CO2) released by microbial decomposition of soil organic carbon on a global scale is approximately five times greater than the amount of…

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers. Oregon State's Olena Taratula and collaborators including OSU postdoctoral researcher Babak Mamnoon and Maureen Baldwin, a physician at Oregon Health & Science University, designed a type of drug nanocarrier known as a polymersome to specifically target a protein in choriocarcinoma cells. Depicted is a polymersome with its methotrexate cargo. Illustration by Parinaz Ghanbari. Image Credit: Parinaz Ghanbari

Improved Treatment Method for Rare Pregnancy-Related Cancer

PORTLAND, Ore. – A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other…